| Literature DB >> 35624883 |
Rosalia Battaglia1, Angela Caponnetto1, Anna Maria Caringella2, Anna Cortone2, Carmen Ferrara1, Salvatore Smirni1, Rossana Iannitti3, Michele Purrello1, Giuseppe D'Amato2, Bernard Fioretti4, Cinzia Di Pietro1.
Abstract
Advanced maternal age impairs reproductive performance, influencing the quantity and the quality of oocytes. Mitochondria dysfunction seems to play a decisive role in conditioning the quality of the female gamete. Different in vitro and in vivo studies, demonstrated the antioxidant and anti-inflammatory activities of Resveratrol and its ability to improve mitochondria function even if the exact mechanism of action has not yet been demonstrated in human oocytes. In this paper, by retrospective analysis, we evaluated follicular fluid (FF) miRNome modification in aged women with a poor ovarian reserve receiving a resveratrol-based supplement the three months before the in vitro Fertilization (IVF) cycle. We found 13 differentially expressed microRNAs (miRNAs) in women treated with resveratrol and specifically miR-125b-5p, miR-132-3p, miR-19a-3p, miR-30a-5p and miR-660-5p, regulating mitochondrial proteins, are able to control metabolism and mitochondrial biogenesis. MiRNA expression differences, observed after resveratrol treatment in FF from women with a poor prognosis for IVF, demonstrated that resveratrol may act on mitomiRNAs to improve follicular microenvironment by transcriptomic and proteomic modifications in granulosa cells.Entities:
Keywords: Resveratrol; microRNAs; mitochondria; poor prognosis women; regulation of gene expression; reproductive aging
Year: 2022 PMID: 35624883 PMCID: PMC9137561 DOI: 10.3390/antiox11051019
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Clinical parameters of women enrolled in the study. Values are reported as mean ± standard deviation or percentage (%). p-values are based on a two-sample t-test. MBI: body mass index; AMH: anti-Müllerian hormone.
| Parameters | Study Group | Control Group | |
|---|---|---|---|
| Patients (N°) | 6 | 6 | |
| Age (Years) | 38 ± 3.3 | 39 ± 3 | 0.29 |
| BMI (kg/m2) | 23.6 ± 3.15 | 22.16 ± 1.8 | 0.37 |
| AMH (ng/mL) | 0.72 ± 0.32 | 0.77 ± 0.43 | 0.31 |
| Antral Follicle Count (N°) | 3.83 ± 1 | 4.16 ± 1 | 0.29 |
| Gonadotropin dosage (IU) | 3425 ± 799 | 3750 ± 1152 | 0.28 |
| Stimulation protocol length (days) | 10.8 ± 1.2 | 10.8 ± 1.2 | 0.5 |
| Follicles (N°) | 8.6 ± 6.5 | 7 ± 4 | 0.29 |
| MII oocytes (N°) | 5.5 ± 3.7 | 5.8 ± 2.7 | 0.4 |
| Pregnancy rate (%) | 50% | 33% |
Figure 1Nanostring miRNA profiling analysis. Volcano plot displaying the differences in fold change (log2FC) of miRNA expression in resveratrol treated FF samples vs. CTRL obtained after data normalization analysis. The x-axis indicates differences in log2FC and the y-axis indicates the −log10 p-value. The horizontal dashed line indicates the threshold for probability of significance (p = 0.05) and the vertical dashed lines set the threshold to 0.5 for the difference in FC of miRNA expression. miRNAs whose expression level is at least 0.5-fold different in resveratrol treated FF samples compared to CTRL, with p < 0.05 corrected for multiple testing by using the Bonferroni method, are indicated by green dots.
List of DE miRNAs in resveratrol treated FF samples vs. CTRL. DE miRNAs were selected according to Volcano Plot and SAM statistical tests. DE miRNAs common to both statistical tests and chosen for further analyses are highlighted in bold. The FC value of each miRNA is reported.
| DE miRNAs | Ttest | SAM | Fold Change Treated vs. Ctrl |
|---|---|---|---|
| miR-1180-3p | X | −1.55 | |
| miR-125b-5p |
|
| −1.76 |
| miR-132-3p |
|
| −2.47 |
| miR-16-5p | X | −1.73 | |
| miR-195-5p | X | −1.53 | |
| miR-19a-3p |
|
| −1.5 |
| miR-30a-5p |
|
| −1.99 |
| miR-30d-5p | X | −1.97 | |
| miR-323a-3p | X | 1.57 | |
| miR-365a-3p + miR-365b-3p | X | −1.79 | |
| miR-497-5p | X | −1.41 | |
| miR-574-5p | X | 2.62 | |
| miR-660-5p |
|
| −1.44 |
Figure 2Relative expression of miRNAs in FF samples. DE miRNA relative expression in resveratrol treated FF samples vs. CTRL is shown by box-and-whisker plots. Expression data are represented as log2normalized counts. Significant p-values corrected for multiple testing by using the Benja-mini-Hochberg method are indicated by <<*>> (* p-value ≤ 0.05).
Figure 3KEGG pathway analysis of DE miRNAs. Functional enrichment analysis of all DE miRNA target genes using KEGG pathway analysis. Log (p-value) is indicated by a yellow-red-coloured key.
Figure 4DE miRNA target genes related to the cellular response to oxidative stress. Regulatory network showing the interaction between miR-125b-5p, miR-132-3p, miR-19a-3p, miR-30a-5p and miR-660-5p and their validated mRNA targets. Orange ellipses represent miRNAs and white rectangles represent mRNA target genes involved in the cellular response to oxidative stress.
Figure 5DE miRNA target genes related to oocyte meiosis. Regulatory network showing the interaction between miR-125b-5p, miR-132-3p, miR-19a-3p, miR-30a-5p, miR-660-5p and their validated mRNA targets. Red ellipses represent miRNAs and white rectangles represent mRNA target genes involved in oocyte meiosis.
Figure 6Impact of Resveratrol supplementation on IVF outcome. (A) Box and whisker plots showing the number (%) of fertilized good quality oocytes (MII) in treated and control groups. Statistically significant p-values (p ≤ 0.05) are indicated by asterisks. (B) Correlation matrix obtained by calculating Pearson correlation coefficients for mitomiR expression (FC) and biochemical pregnancy scores. The correlation values are indicated by a color gradient from green (negative correlation) to red (positive correlation), as shown in the colored bar. Statistically significant p-values (p ≤ 0.05) are indicated by asterisks. (C) Scatterplot on miRNAs tightly correlated and showing the best-fit line obtained from linear regression analysis.